

in lacs

		CONSOLIDATED			
Particulars		Quarter Ended on 30 th June 2012	Quarter Ended on 31 st March 2012	Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2012
PART- I					
1	(a) Net Sales / Income from Operations				
	Domestic	22,870	20,373	20,723	87,718
	Exports	13,936	13,857	13,749	59,071
	Total	36,806	34,230	34,472	146,789
	Less : Excise Duty	199	151	145	554
	Net Sales / Income from Operations	36,607	34,079	34,327	146,235
	(b) Other Operating Income	70	182	40	404
	Total Income from Operations	36,677	34,261	34,367	146,639
2	Expenses				
	(a) Decrease/(increase) in stock in trade and work in progress	(142)	(3,435)	(1,174)	(6,444)
	(b) Consumption of Raw Materials & Packing Materials	11,168	12,684	11,802	52,824
	(c) Purchase of traded goods	6,415	6,055	6,545	24,412
	(d) Employees' Cost	4,495	4,311	4,174	16,846
	(e) Research and Development Expense	1,389	2,214	1,209	5,858
	(f) Excise Duty	114	311	(8)	509
	(g) Other Expenditure	8,011	8,011	6,784	30,593
	Total Expenses	31,450	30,149	29,332	124,597
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	5,227	4,111	5,035	22,041
4	Other Income	22	13	8	44
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	5,249	4,125	5,043	22,086
6	Depreciation	866	892	819	3,365
7	Interest (Net)	574	538	677	2,621
8	Net Profit / (Loss) from Ordinary Activities before Tax	3,809	2,694	3,547	16,099
9	Tax Expense				
	Less : Provision for Current Tax	731	526	723	3,123
	Less/(Add) : Provision for Deferred Tax Liability /(Assets)	(5)	137	68	(38)
10	Net Profit / (Loss) from Ordinary Activities after Tax	3,083	2,031	2,756	13,014
11	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve				35,730
13	Debenture Redemption Reserve				3,125
14	Basic & Diluted EPS (Not Annualised)	1.64	1.08	1.46	6.90
15	Debt Equity Ratio	-	-	-	0.94
16	Debt Service Coverage Ratio	-	-	-	3.06
17	Interest Service Coverage Ratio	-	-	-	12.40
PART- II					
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48763089	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139752825	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter ended on 30th June, 2012			
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	NIL			
	Disposed of during the quarter	NIL			
	Remaining unresolved at the end of the quarter	NIL			

in lacs

	Particulars	STANDALONE			
		Quarter Ended on 30 th June 2012	Quarter Ended on 31 st March 2012	Quarter Ended on 30 th June 2011	Year Ended on 31 st March 2012
		PART- I			
1	(a) Net Sales / Income from Operations				
	Domestic	22,870	20,373	20,723	87,718
	Exports	11,200	11,454	11,551	49,961
	Total	34,070	31,827	32,274	137,679
	Less : Excise Duty	199	151	145	554
	Net Sales / Income from Operations	33,871	31,676	32,129	137,125
	(b) Other Operating Income	70	182	40	404
	Total Income from Operations	33,941	31,857	32,169	137,528
2	Expenses				
	(a) Decrease/(increase) in stock in trade and work in progress	(142)	(3,435)	(1,174)	(6,444)
	(b) Consumption of Raw Materials & Packing Materials	11,168	12,684	11,802	52,824
	(c) Purchase of traded goods	4,068	4,110	4,556	16,779
	(d) Employees' Cost	4,495	4,311	4,174	16,846
	(e) Research and Development Expense	1,389	2,214	1,209	5,858
	(f) Excise Duty	114	311	(8)	509
	(g) Other Expenditure	8,021	7,712	6,680	30,200
	Total Expenses	29,113	27,906	27,239	116,571
3	Profit from Operations before Other Income, Interest, Depreciation & Exceptional Items	4,828	3,951	4,930	20,957
4	Other Income	22	13	8	44
5	Profit/(Loss) from Ordinary Activities before Interest, Depreciation, & Exceptional Items	4,850	3,964	4,938	21,001
6	Depreciation	866	892	819	3,365
7	Interest (Net)	574	538	677	2,621
8	Net Profit / (Loss) from Ordinary Activities before Tax	3,410	2,534	3,442	15,015
9	Tax Expense				
	Less : Provision for Current Tax	687	508	711	3,000
	Less /Add : Provision for Deferred Tax Liability/(Assets)	(5)	137	68	(38)
10	Net Profit / (Loss) from Ordinary Activities after Tax	2,728	1,890	2,663	12,054
11	Paid up Equity Share Capital (Face value of share ` 2/-)	3,770	3,770	3,770	3,770
12	Reserves excluding Revaluation Reserve				32,316
13	Debenture Redemption Reserve				3,125
14	Basic & Diluted EPS (Not Annualised)	1.45	1.00	1.41	6.39
15	Debt Equity Ratio	-	-	-	1.02
16	Debt Service Coverage Ratio	-	-	-	2.91
17	Interest Service Coverage Ratio	-	-	-	11.76
	PART- II				
A	Particulars of Shareholding				
1	Public Shareholding				
	- Number of Shares	48777294	48763089	48763089	48763089
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
2	Promoters and Promoter Group Shareholding				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139752825	139752825	139752825
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
B	INVESTOR COMPLAINTS	Quarter ended on 30th June, 2012			
	Pending at the beginning of the quarter	NIL			
	Received during the quarter	NIL			
	Disposed of during the quarter	NIL			
	Remaining unresolved at the end of the quarter	NIL			

Notes :

- 1 The above results, which includes unaudited results of the Subsidiary, have been duly reviewed by Statutory Auditors, were recommended by the Audit Committee and were approved by Board of Directors. The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website www.alembic-india.com.
- 2 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).

For Alembic Pharmaceuticals Limited

Place : Vadodara
Date : 9th Aug, 2012

Chirayu Amin
Chairman and Managing Director

Visit us at www.alembic-india.com